Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression
Ghulam Hassan Dar1, Vijaya Gopal, N Madhusudhana Rao
1CSIR-Centre for Cellular and Molecular Biology , Uppal Road, Hyderabad 500007, Andhra Pradesh, India.
Molecular Pharmaceutics
|December 30, 2014
Summary
Novel lipid nanoparticles effectively deliver small interfering RNA (siRNA) to tumors. This formulation enhances siRNA bioavailability and achieves significant gene silencing and tumor suppression in mice with minimal toxicity.
Area of Science:
- Biotechnology
- Nanomedicine
- Gene Therapy
Background:
- Lipid-based nanoparticles are promising for siRNA delivery but face challenges with in vivo efficiency due to serum protein adsorption and charge.
- Formulation strategies critically impact lipid-siRNA complex stability, siRNA degradation, and bioavailability.
- Serum protein adsorption and complex charge influence siRNA's in vivo half-life and efficacy.
Purpose of the Study:
- To develop a novel lipid nanoparticle formulation for enhanced in vivo siRNA delivery.
- To investigate the impact of specific lipid components on nanoparticle stability and tumor targeting.
- To evaluate the therapeutic efficacy and safety of the developed siRNA-loaded nanoparticles.
Main Methods:
- Formulation of siRNA-encapsulated vesicles (SEVs) using a dihydroxy cationic lipid (DHDEAC), cholesterol, and DSPE-PEG 2000 via ethanol dilution.
- Biodistribution studies in xenograft mice using live animal imaging and fluorescence microscopy.
- Assessment of gene silencing, tumor suppression, and safety parameters in an SK-OV-3 xenograft mouse model.
Main Results:
- Stable and homogeneous SEVs were formed with DHDEAC-based lipids and DSPE-PEG 2000.
- SEVs demonstrated selective tumor accumulation in xenograft mice.
- Intravenous administration of SEVs resulted in significant gene silencing (ErbB2, AURKB) and tumor suppression.
- The formulation exhibited a non-toxic profile based on hepatocellular injury markers.
Conclusions:
- DHDEAC-based lipid nanoparticles improve siRNA pharmacokinetics and enable effective in vivo delivery.
- The developed formulation shows potential for targeted gene therapy and cancer treatment.
- This formulation strategy offers a promising approach to overcome challenges in siRNA delivery for therapeutic applications.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
144
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
144
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
132
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
132
01:27Bioavailability Enhancement: Drug Permeability Enhancement
318
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
318